Navigation Links
Malaria drug target raises hopes for new treatments
Date:12/22/2013

Scientists have taken an important step towards new malaria treatments by identifying a way to stop malaria parasites from multiplying.

In a study published in Nature Chemistry, they show that blocking the activity of an enzyme called NMT in the most common malaria parasite prevents mice from showing symptoms and extends their lifespan. The team are working to design molecules that target NMT more potently, and hope to start clinical trials of potential treatments within four years.

A recent study estimated that 1.2 million people died from malaria in 2010. Although a variety of antimalarial drugs are available, some strains of the parasite are resistant to treatment. These strains are becoming more common, with treatment failures reported across multiple frontline drugs. If acute illness is cured, the parasite can remain dormant in the blood and return to cause illness later. Malaria vaccines have been researched intensively, but none have been introduced into clinical practice.

The new study shows that NMT is involved in a wide range of essential processes in the parasite cell, including the production of proteins that enable malaria to be transmitted between humans and mosquitoes, and proteins that enable malaria to cause long-term infection.

The researchers have tested a handful of molecules that block the activity of NMT in the parasite living inside human red blood cells, and in mice, but further refinement will be needed before a treatment is ready to be tested in humans.

Dr Ed Tate, from the Department of Chemistry at Imperial College London, who led the project, said: "The drug situation for malaria is becoming very serious. Resistance is emerging fast and it's going to be a huge problem in the future.

"Finding an enzyme that can be targeted effectively in malaria can be a big challenge. Here, we've shown not only why NMT is essential for a wide range of important processes in the parasite, but also that we can design molecules that stop it from working during infection. It has so many functions that we think blocking it could be effective at preventing long-term disease and transmission, in addition to treating acute malaria. We expect it to work not just on Plasmodium falciparum, the most common malaria parasite, but the other species as well.

"We need to do some more work in the lab to find the best candidate molecule to take into clinical trials, but hopefully we'll be ready to do that within a few years."


'/>"/>

Contact: Gail Wilson
gail.wilson@imperial.ac.uk
44-207-594-6702
Imperial College London
Source:Eurekalert

Related biology news :

1. Malaria conference looks to Israels past for modern solutions
2. Study finds new vulnerability in malaria parasite
3. Using data to fight malaria
4. Control malaria by segmenting sleeping arrangements
5. New research finds potential risk for millions in Africa believed resistant to vivax malaria
6. Vivax malaria may be evolving around natural defense
7. Low-dose treatment may block malaria transmission
8. New malaria vaccines roadmap targets next generation products by 2030
9. Holograms offer hope in fight against malaria, study suggests
10. CWRU grants Disease Diagnostic Group option on malaria diagnostic device
11. NIH fellowship helps researcher fight malaria, understand mosquito immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... 23, 2017  Today, the Fisher Center for Alzheimer,s ... an important study that could lead to the development ... Alzheimer,s disease. This groundbreaking research was conducted by the ... Nobel Laureate Dr. Paul Greengard , in the ... Fisher Center scientists have linked a mutation that ...
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... to the fostering of technology and monetization of intellectual ... infringement lawsuits. Anthony Hayes , Chief ... we will continue to communicate with shareholders about the ... our due diligence on other patent assets that fit ...
(Date:1/23/2017)... , January 23, 2017 Atlas ... announces completion of its Series D financing, raising $35 million ... new investor, Wondfo Biotech. ... Development of the Atlas Genetics io® system ... Chlamydia trachomatis (CT) test announced in February 2016.  This new ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica from ... and host a hands-on workshop for surgeons to experience the simplicity of the ...
Breaking Biology Technology: